Ms C

  • Unable to sleep due to night sweats. Hot flushes severely impacting daily life
  • Bleeding problems on HRT
  • CV co-morbidities

Age: 57

Ms C

Menopause Symptoms at Initiation

  • Completely unable to sleep due to night sweats 
  • On a bad day/night hot flushes every 15 minutes​.
  • Severe impact on daily life
  • Onset of hot flushes & night sweats: 4 years ago

Medical history and comorbidities

  • Atrial Fibrillation
  • Hypertension
  • Chronic Kidney Disease
  • Vertigo

Basis for treatment decision

  • HRT caused bleeding problems
  • Did not want side effects associated with Oxybutynin^

Response to treatment with VEOZA

  • 0 hot flushes at night
  • 0-10 in the day

VMS at 3 Months of Veoza Treatment

  • Good – 50-60% reduction in hot flushes
  • No more night sweats, resulting in dramatically improved sleep
  • Some hot flushes in the day but much more manageable
  • Treated with Veoza for 12 months at time of reporting

Adverse Events

  • None reported

Clinician’s comments

“I think it’s impossible to overestimate the impact that improved sleep quality has on wellbeing. This lady was struggling to function, her life ruled by night sweats and hot flushes occurring day and night. She felt exhausted. VEOZA reduced the frequency of VMS, but had a particularly beneficial impact on symptoms during the night, allowing her sleep, energy levels and brain function to recover. She was extremely averse to HRT and so relieved to find an effective treatment she could have. She still experiences good and not so good days but the improvement in her sleep quality has enabled normal functioning. My patient is relieved to have found a suitable treatment for her”.

Fast relief of hot flushes & night sweats.

Fast relief of hot flushes & night sweats. 1 dose a day, no titration.1,2

VEOZA is not recommended in patients with severe renal impairment or with end-stage renal disease. 

^Oxybutynin is not licensed for vasomotor symptoms associated with menopause and therefore this treatment would be off-label. 

HRT, hormone replacement therapy

 

REFERENCES: 1. VEOZA Summary of Product Characteristics. 2. Data on file Data on File: ref 40499


Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, Website: www.hpra.ie or Astellas Pharma Co. Ltd. Tel:+353 1 467 1555, E-mail: irishdrugsafety@astellas.com.
 

MAT-IE-VEO-2025-00074 January 2026